Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Semaglutide and Tirzepatide
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
Lilly's tirzepatide challenges semaglutide in obesity drug market
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem
Axios on MSN
1h
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from ...
17h
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
23h
on MSN
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
1d
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
TCTMD
19h
Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Wegovy
Glucagon-like peptide-1
Feedback